EA201992220A1 - Комбинированная терапия для лечения или предупреждения опухолей - Google Patents

Комбинированная терапия для лечения или предупреждения опухолей

Info

Publication number
EA201992220A1
EA201992220A1 EA201992220A EA201992220A EA201992220A1 EA 201992220 A1 EA201992220 A1 EA 201992220A1 EA 201992220 A EA201992220 A EA 201992220A EA 201992220 A EA201992220 A EA 201992220A EA 201992220 A1 EA201992220 A1 EA 201992220A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tumors
prevention
treatment
combined therapy
epoxytiglian
Prior art date
Application number
EA201992220A
Other languages
English (en)
Inventor
Пол Уоррен Реддел
Джейсон Кингсли Каллен
Глен Мэтью Бойль
Питер Гордон Парсонс
Виктория Энн Гордон
Original Assignee
Кьюбиотикс Пти Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901027A external-priority patent/AU2017901027A0/en
Application filed by Кьюбиотикс Пти Лтд filed Critical Кьюбиотикс Пти Лтд
Publication of EA201992220A1 publication Critical patent/EA201992220A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к комбинированной терапии опухолей, включающей введение эпокситиглианового соединения и ингибитора контрольной точки иммунитета. В отдельных вариантах осуществления - это способ лечения опухоли и/или лечения или предупреждения одной или нескольких сторонних опухолей с помощью такой терапии. Также описываются фармацевтические композиции и наборы, содержащие эпокситиглиановые соединения и ингибиторы контрольной точки иммунитета.
EA201992220A 2017-03-23 2018-03-23 Комбинированная терапия для лечения или предупреждения опухолей EA201992220A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017901027A AU2017901027A0 (en) 2017-03-23 Combination Therapy
PCT/AU2018/050277 WO2018170559A1 (en) 2017-03-23 2018-03-23 Combination therapy for the treatment or prevention of tumours

Publications (1)

Publication Number Publication Date
EA201992220A1 true EA201992220A1 (ru) 2020-02-11

Family

ID=63583892

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992220A EA201992220A1 (ru) 2017-03-23 2018-03-23 Комбинированная терапия для лечения или предупреждения опухолей

Country Status (28)

Country Link
US (1) US11213506B2 (ru)
EP (1) EP3600281B1 (ru)
JP (1) JP6905075B2 (ru)
KR (1) KR102228055B1 (ru)
CN (1) CN110461324A (ru)
AU (1) AU2018238202B2 (ru)
BR (1) BR112019019748A2 (ru)
CA (1) CA3056685C (ru)
DK (1) DK3600281T3 (ru)
EA (1) EA201992220A1 (ru)
ES (1) ES2953575T3 (ru)
FI (1) FI3600281T3 (ru)
HR (1) HRP20230936T1 (ru)
HU (1) HUE063299T2 (ru)
IL (1) IL269522B2 (ru)
LT (1) LT3600281T (ru)
MX (1) MX2019011221A (ru)
MY (1) MY197427A (ru)
NZ (1) NZ756754A (ru)
PH (1) PH12019502132A1 (ru)
PL (1) PL3600281T3 (ru)
PT (1) PT3600281T (ru)
RS (1) RS64472B1 (ru)
SG (1) SG11201907891XA (ru)
SI (1) SI3600281T1 (ru)
UA (1) UA125614C2 (ru)
WO (1) WO2018170559A1 (ru)
ZA (1) ZA201906001B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1971588T3 (pl) * 2005-12-23 2013-01-31 Qbiotics Ltd Pochodne tiglien-3-onu
KR102423377B1 (ko) 2013-08-05 2022-07-25 트위스트 바이오사이언스 코포레이션 드 노보 합성된 유전자 라이브러리
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
WO2016172377A1 (en) 2015-04-21 2016-10-27 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
CN108368482A (zh) 2015-09-18 2018-08-03 特韦斯特生物科学公司 寡核酸变体文库及其合成
KR20180058772A (ko) 2015-09-22 2018-06-01 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
KR102217487B1 (ko) 2016-09-21 2021-02-23 트위스트 바이오사이언스 코포레이션 핵산 기반 데이터 저장
EP3586255A4 (en) 2017-02-22 2021-03-31 Twist Bioscience Corporation NUCLEIC ACID-BASED DATA STORAGE
CA3066744A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CA3075505A1 (en) 2017-09-11 2019-03-14 Twist Bioscience Corporation Gpcr binding proteins and synthesis thereof
GB2583590A (en) 2017-10-20 2020-11-04 Twist Bioscience Corp Heated nanowells for polynucleotide synthesis
AU2019270243A1 (en) 2018-05-18 2021-01-07 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
SG11202109283UA (en) 2019-02-26 2021-09-29 Twist Bioscience Corp Variant nucleic acid libraries for antibody optimization
US20220193023A1 (en) 2019-04-12 2022-06-23 QBiotics Pty Ltd Method of treating tumours
MX2021015673A (es) * 2019-06-19 2022-02-03 QBiotics Pty Ltd Alteracion de biopelicula.
CN114729342A (zh) 2019-06-21 2022-07-08 特韦斯特生物科学公司 基于条形码的核酸序列装配
MX2022006995A (es) * 2019-12-09 2022-10-27 Twist Bioscience Corp Bibliotecas de acidos nucleicos variantes para receptores de adenosina.
KR20220151333A (ko) 2021-05-06 2022-11-15 한국과학기술연구원 가시광선에 의해 활성화되는 항암 면역치료용 나노입자 및 이의 용도
WO2023115123A1 (en) * 2021-12-21 2023-06-29 QBiotics Pty Ltd Crystalline intermediates
WO2023154984A1 (en) * 2022-02-17 2023-08-24 QBiotics Pty Ltd Combination therapies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006268148B2 (en) * 2005-07-13 2012-11-01 Salvia Sciences, Inc. Ester prodrugs of prostratin and related phorbol compounds
PL1971588T3 (pl) * 2005-12-23 2013-01-31 Qbiotics Ltd Pochodne tiglien-3-onu
CN105308052B (zh) 2013-04-18 2018-07-10 Q生物有限公司 用于伤口愈合的方法和组合物
WO2015133596A1 (ja) * 2014-03-07 2015-09-11 国立大学法人京都大学 細胞培養用組成物
US10765710B2 (en) 2014-07-16 2020-09-08 Institut Gustave-Roussy Combination of oncolytic virus with immune checkpoint modulators
AU2015330731B2 (en) 2014-10-10 2020-07-09 Idera Pharmaceuticals, Inc. Treatment of cancer using TLR9 agonist with checkpoint inhibitors
CN104926758A (zh) * 2015-05-22 2015-09-23 南京泽朗医药科技有限公司 斑籽素的制备方法及其在抗白血病药物中的应用
WO2017024009A1 (en) * 2015-08-03 2017-02-09 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof

Also Published As

Publication number Publication date
LT3600281T (lt) 2023-09-11
DK3600281T3 (da) 2023-08-14
IL269522B1 (en) 2024-01-01
KR20190126431A (ko) 2019-11-11
JP6905075B2 (ja) 2021-07-21
NZ756754A (en) 2024-02-23
US11213506B2 (en) 2022-01-04
FI3600281T3 (fi) 2023-08-24
IL269522A (ru) 2019-11-28
AU2018238202B2 (en) 2024-03-28
SI3600281T1 (sl) 2023-10-30
MY197427A (en) 2023-06-16
PL3600281T3 (pl) 2023-09-11
CN110461324A (zh) 2019-11-15
JP2020511512A (ja) 2020-04-16
AU2018238202A8 (en) 2024-03-28
IL269522B2 (en) 2024-05-01
MX2019011221A (es) 2019-11-01
CA3056685C (en) 2024-01-16
EP3600281A1 (en) 2020-02-05
EP3600281B1 (en) 2023-05-31
UA125614C2 (uk) 2022-05-04
WO2018170559A1 (en) 2018-09-27
PH12019502132A1 (en) 2020-07-06
AU2018238202A1 (en) 2019-09-19
ZA201906001B (en) 2023-12-20
BR112019019748A2 (pt) 2020-04-14
PT3600281T (pt) 2023-09-04
ES2953575T3 (es) 2023-11-14
SG11201907891XA (en) 2019-09-27
US20200030279A1 (en) 2020-01-30
EP3600281A4 (en) 2020-03-18
HRP20230936T1 (hr) 2023-11-24
CA3056685A1 (en) 2018-09-27
KR102228055B1 (ko) 2021-03-16
RS64472B1 (sr) 2023-09-29
HUE063299T2 (hu) 2024-01-28

Similar Documents

Publication Publication Date Title
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
EA202190630A1 (ru) Способы комбинированной терапии
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
PH12018500642A1 (en) Anti-garp antibody
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
EA201792186A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
EA201692285A1 (ru) Ингибиторы ezh2 для лечения лимфомы
EA201692480A1 (ru) Фармацевтическая композиция
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201890567A1 (ru) Способ лечения рака
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
EA202190749A1 (ru) Способы комбинированной терапии
EA201792580A1 (ru) Ингибиторы ido
EA202190776A1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
BR112017013982A2 (pt) fármaco de combinação
EA201792288A1 (ru) Способы лечения рака
EA201990508A1 (ru) ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2